TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 616497285
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments (fasting, rehydration, acid suppression, inhibition of pancreatic enzyme activity, use of antibiotics)
Study: 33731586
Drug: Hemoclips monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoclips monotherapy
Study: 33731586
Drug: Hemoclips combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoclips combination therapy
Study: 33731586
Drug: Hemoclips combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoclips combination therapy (in antithrombotic subgroup)
Study: 33731586
Drug: Hemoclips combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoclips combination therapy (after propensity score matching)
Study: 32348985
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg IV ferric derisomaltose
Study: 35028890
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Group (HDG) - 3750 IU VD3/day
Study: 35028890
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Group (LDG) - 600 IU VD3/day
Study: 35017261
Drug: Cigarette packs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette packs with background colour and capsule image
Study: 35017261
Drug: Cigarette packs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette packs displaying a flavour name, background colour or capsule image
Study: 35968208
Drug: Symbiotic (Pedilact)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic (Pedilact) - 5 drops containing Lactobacillus reuteri and simethicone (20 mg twice daily) for 4 weeks
Study: 35075138
Drug: Capecitabine chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine chemotherapy alone or in combination with bevacizumab (± mitomycin C)
Study: 34552008
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus palifosfamide with MRP-1 inhibitors (nilotinib or avapritinib)
Study: 34552008
Drug: MRP-1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, avapritinib)
Study: 35110894
Drug: Ultrasound-guided PECS
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PECS I (0.2 ml/kg) and PECS II (0.4 ml/kg) block, post-induction with 0.25% levobupivacaine, maximum dose of 2 mg/kg.
Study: 32278103
Drug: Increased abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased abdominal pressure using a 3000 ml bag of normal saline (NS)
Study: 34106667
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special treatment (Control group)
Study: 35341689
Drug: Tisagenlecleucel CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisagenlecleucel CAR-T therapy
Study: 34489296
Drug: Development and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development and use of a tapering schedule
Study: 32492138
Drug: 150 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/d of resveratrol (n = 20)
Study: 33248530
Drug: IPR enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPR enhanced with youth- and parent-directed online Single-Session Interventions (SSIs) designed to reduce youths’ internalizing symptoms and improve parents’ mental health treatment expectancies.
Study: 35334836
Drug: Three eggs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three eggs per day for 4 weeks (choline equivalent of 400 mg/day)
Study: 35334836
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline bitartrate (CB) supplement for 4 weeks (choline equivalent of 400 mg/day)
Study: 32936010
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets)
Study: 32936010
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone
Study: 34705283
Drug: Isatuximab (Isa)
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab (Isa) 10 mg/kg weekly for 4 weeks then every 2 weeks (QW-Q2W) in combination with pomalidomide/dexamethasone (Pd)
Study: 34705283
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a monthly dosing regimen of Isatuximab after 6 months
Study: 34705283
Drug: Isatuximab (Isa)
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab (Isa) 10 mg/kg QW-Q2W regimen
Study: 35866676
Drug: Mouthwash with
Normalized name: Sodium Fluoride 0.02% Oromucosal Solution [REMBRANDT WHITENING MOUTHWASH WITH FLUORIDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash with Sambucus williamsii var. coreana extract (5 days treatment)
Study: 33646464
Drug: Chemotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy of physician’s choice
Study: 33389399
Drug: CTC-oriented personalized
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC-oriented personalized adjuvant therapy (experimental group, n = 68)
Study: 36334308
Drug: Low-dose cognitively
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cognitively engaging movement games (20-min)
Study: 36334308
Drug: High-dose cognitively
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cognitively engaging movement games (40-min)
Study: 35623869
Drug: l-Carnitine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine (3000 mg/day) for 7 days
Study: 33594771
Drug: Concomitant durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant durvalumab during chemo/radiation therapy
Study: 33594771
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy during chemo/radiation therapy
Study: 33850272
Drug: Sustained-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release isosorbide mononitrate (40–60 mg)
Study: 32233338
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg) plus lifestyle therapy
Study: 32233338
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus lifestyle therapy
Study: 34879493
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (10%)
Study: 32770972
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (loading dose of 20,000 or 40,000 IU daily for the first 11 days, followed by a maintenance dose of 2000 IU daily)
Study: 33752070
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg ASTA
Study: 33752070
Drug: 40 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 and 80 mg/kg ASTA
Study: 33752070
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg ASTA (Control)
Study: 32836109
Drug: Treatment (Escitalopram)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (Escitalopram)
Study: 35521002
Drug: Pharmaceutical service
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical service intervention
Study: 34987595
Drug: Continuous Acupuncture
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Acupuncture Treatment (CAT) group - 5 times/week for 4 weeks
Study: 34987595
Drug: Intermittent Acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Acupuncture Treatment (IAT) group - 3 times/week for 4 weeks
Study: 33162599
Drug: Etomidate infusion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate infusion at a rate of 0.07 mg kg‐1 min‐1
Study: 33162599
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion of 0.7 mg kg‐1 min‐1
Study: 33743292
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g protein/kg body weight (BW)/d
Study: 33743292
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g protein/kg BW/d (standard group)
Study: 34838305
Drug: NaCl (twice/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (twice/day application for 5 days by caregiver)
Study: 34031451
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (assumed increase of 20 nmol/L in 25OHD)
Study: 32101256
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg every 4 weeks
Study: 39009804
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg every 2 weeks
Study: 32101256
Drug: Lebrikizumab (high-dose)
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab (high-dose)
Study: 35188581
Drug: Brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab 6 mg loading (three monthly loading doses)
Study: 35188581
Drug: Brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab 6 mg non-loading (one initial injection)
Study: 32861442
Drug: G-TL medium
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-TL medium
Study: 35227250
Drug: Cell-free and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-free and concentrated ascites reinfusion therapy (CART)
Study: 35373003
Drug: TAKE (taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAKE (taking BP medications as prescribed)
Study: 35373003
Drug: HOLD (holding
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOLD (holding BP medications dosed more than once daily)
Study: 32393654
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin (IA) with bone marrow mononuclear cells (MNCs)
Study: 32393654
Drug: Regular atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular atorvastatin (RA) with bone marrow mononuclear cells (MNCs)
Study: 32393654
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin (IA) with placebo
Study: 32075667
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tDCS and attention to the APB muscle
Study: 32227161
Drug: No cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No cream
Study: 35134768
Drug: Passive suspension
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive suspension system 'Levitas' (Technomex, Poland)
Study: 34426552
Drug: Multicomponent training
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent training program (daily activities, dancing, gardening, sports/games) twice weekly for 3 months
Study: 33769656
Drug: Henagliflozin 10
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 10 mg
Study: 33769656
Drug: Henagliflozin 5
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 5 mg and 10 mg
Study: 35972485
Drug: Remote Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischemic Conditioning (RIC) for 10 to 14 days as an adjunct to guideline-based treatment (n=922)
Study: 35972485
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment alone (Control group, n=971)
Study: 35972485
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment alone (Control group)
Study: 34146045
Drug: Anti-VEGF therapy
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF therapy with SHRM
Study: 34709526
Drug: Pills
Normalized name: Lax-Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills
Study: 34164944
Drug: Belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg IV plus standard therapy
Study: 33977619
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of medications during pregnancy (multivitamins, analgesics, folic acid)
Study: 33977619
Drug: Attitudes towards
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Attitudes towards medication use during pregnancy
Study: 33977619
Drug: Association between
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association between nationality and occupation with attitudes about medications
Study: 33250271
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with radiotherapy ± chemotherapy
Study: 32567372
Drug: Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules combined with vitamin E ointment (Control)
Study: 616857406
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application social support program via Line, twice per week for 4 weeks after childbirth
Study: 32738837
Drug: IV levonadifloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV levonadifloxacin 800 mg
Study: 32738837
Drug: Oral levonadifloxacin
Normalized name: levofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levonadifloxacin 1000 mg
Study: 34475155
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg secukinumab (pharmacological control group)
Study: 34475155
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg secukinumab (75% dose reduction)
Study: 34475155
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg secukinumab + novel tasting drink (group 3)
Study: 32242820
Drug: Smartphone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based cognitive behavior therapy (CBT) TBHC intervention for pain self-management, 8 weeks, daily or every other day interaction
Study: 35263650
Drug: Medication abortions
Normalized name: ALCOHOL 82 mL in 100 mL TOPICAL LIQUID [Bortons Ethyl Rubbing Alcohol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication abortions
Study: 33563104
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 mg two times daily
Study: 35263688
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy according to an algorithm based on individualized nutritional requirements
Study: 32845782
Drug: Tetravalent Influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent Influenza Vaccine (TetIV)
Study: 32845782
Drug: Trivalent Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Influenza Vaccine (TriIV)
Study: 32621903
Drug: Endoscopic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic and minimally invasive surgical therapies for GERD
Study: 35910816
Drug: Paracervical block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical block (4 ml of lidocaine at 4 and 8 o’clock positions)
Study: 35910816
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conscious sedation (30 mg pentazocine and 10 mg diazepam)
Study: 36802321
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly (QM)
Study: 34187382
Drug: 60 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg/day vitamin C as a continuous infusion for 96 hours
Study: 33783553
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (2.5 mg)
Study: 34558214
Drug: Intraoperative amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative amino acid (AA) infusion
Study: 36370961
Drug: Turmeric/piperine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric/piperine (3 g turmeric + 2 mg piperine/day)
Study: 36370961
Drug: Turmeric (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (3 g/day)
Study: 33197609
Drug: 12-month online
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month online behavioral lifestyle intervention (BLI) with adjunct components
Study: 34671099
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml 24% oral sucrose
Study: 34671099
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml 30% oral dextrose
Study: 34605040
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation and laughter therapy for 40 minutes per session for 3-4 sessions
Study: 35208555
Drug: Arthrocen 300
Normalized name: AVOCADO OIL UNSAPONIFIABLES 100 mg / SOYBEAN 200 mg ORAL CAPSULE [ARTHROCEN 300 mg]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocen 300 mg/day
Study: 32204554
Drug: Migratens® Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migratens® Group (nutraceutical treatment with coenzyme Q10, vitamin D, alpha‐lipoic acid, magnesium, and tryptophan)
Study: 32204554
Drug: Acupuncture Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture Group (acupuncture treatment according to traditional Chinese medicine principles)
Study: 36134849
Drug: Surgical Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Assessment Tool (SAT) administered at remote hospitals
Study: 33562729
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of specific collagen peptides (CP‐G)
Study: 33562729
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (P‐G)
Study: 35542991
Drug: Aducanumab high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab high dose (10 mg/kg target dose)
Study: 35542991
Drug: Aducanumab low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab low dose (3 or 6 mg/kg target dose)
Study: 32785036
Drug: Phytosterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol (2 g of free‐phytosterols nanoparticles daily for six months)
Study: 34542900
Drug: Nomogram integrating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomogram integrating tumor extension, surgery type, radiotherapy, and chemotherapy
Study: 33418053
Drug: Subcutaneous allergy
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergy immunotherapy (3-year course)
Study: 33441350
Drug: D-mannose powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-mannose powder daily for 6 months
Study: 33441350
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder daily for 6 months
Study: 35953331
Drug: FRIL (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRIL (20 μg)
Study: 35953331
Drug: CTB-ACE2 (0.925
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTB-ACE2 (0.925 μg)
Study: 34256319
Drug: Dose-escalated intensity-modulated
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated intensity-modulated radiotherapy (DE-IMRT)
Study: 34256319
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose intensity-modulated radiotherapy (ST-IMRT)
Study: 34002559
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and swallowing function rehabilitation training (Control)
Study: 33308810
Drug: High-velocity, low-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity, low-load resistance exercise once weekly (HVLL1)
Study: 33308810
Drug: Low-velocity, high-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-velocity, high-load resistance exercise once weekly (LVHL1)
Study: 33308810
Drug: High-velocity, low-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-velocity, low-load resistance exercise twice weekly (HVLL2)
Study: 33308810
Drug: Low-velocity, high-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-velocity, high-load resistance exercise twice weekly (LVHL2)
Study: 35639792
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (400,000 IU)
Study: 35639792
Drug: Standard-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cholecalciferol (50,000 IU)
Study: 34108081
Drug: Aminoglycosides administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides administered in a predialysis schedule
Study: 34108081
Drug: Aminoglycosides administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides administered in a postdialysis schedule
Study: 33225600
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of pain management 'other' than analgesia
Study: 33225600
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral analgesia